Here, we report an unexpected and functional epigenetic mini‐circuit of AML1‐ETO/THAP10/miR‐383 in t(8;21) AML, which might represent a novel therapeutic target as well as a biomarker for predicting clinical outcome of patients with AML. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.